X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, AstraZeneca leverages the AZP-3601 (neboparatide), peptide agonist of the PTH1 receptor. Currently, being evaluated in the Phase III for the treatment of Chronic Hypoparathyroidism, Endocrine System Diseases, and Parathyroid Diseases.
Lead Product(s): Eneboparatide
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $1,000.0 million Upfront Cash: $800.0 million
Deal Type: Acquisition March 14, 2024
Details:
AZP-3813, a peptide GHR antagonist, is being developed as a potential treatment for acromegaly to be used in combination with somatostatin analogues (SSAs) for patients who do not adequately respond to SSAs alone.
Lead Product(s): AZP-3813
Therapeutic Area: Endocrinology Product Name: AZP-3813
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: PeptiDream
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
AZP-3601 (eneboparatide) targets PTH receptor to safely produce sustained blood levels of calcium and thereby manage the symptoms of hypoparathyroidism, and to limit urine calcium excretion by restoring calcium reabsorption by the kidney, preventing chronic kidney disease.
Lead Product(s): Eneboparatide
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
Amolyt will advance pre-clinical development of AZP-40XX, an anti-PTHR1 monoclonal antibody, as potential treatments of primary hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy (HHM).
Lead Product(s): AZP-40XX
Therapeutic Area: Endocrinology Product Name: AZP-40XX
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: XOMA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 24, 2023
Details:
Amolyt plans to use the proceeds to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601, now known as eneboparatide, for the treatment of hypoparathyroidism, and AZP-3813 for the treatment of acromegaly.
Lead Product(s): Eneboparatide
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Sofinnova Partners
Deal Size: $138.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 06, 2023
Details:
AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyroidism.
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyroidism.
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyroidism.
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
AZP-3601, a long-acting PTH analog as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly.
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of PTH receptor to safely produce sustained and stable levels of calcium in blood with goal of consequently preventing chronic kidney disease.
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
